By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Investing > Investing In Value Stocks – Prudent Speculator Picks: PFE & PYPL
Investing

Investing In Value Stocks – Prudent Speculator Picks: PFE & PYPL

News Room
Last updated: 2023/09/08 at 2:49 AM
By News Room
Share
5 Min Read
SHARE

The Prudent Speculator, the value-oriented investment newsletter I have edited for more than three decades, has been guided–through thick and thin–by three core tenets: patience, selection and diversification.

Contents
HIGH-YIELDING PHARMA TITANFORMER GROWTH STOCK NOW A VALUE NAME

I believe selection improves the odds of success and have always championed value investing, which is the ownership of assets at bargain prices. At the core is the notion that today’s price is below the future value. In practice, I am happy to pay a low price for a stock today that I expect is going to be worth more in the future.

Despite sharing the same ultimate target of capital appreciation with Growth investors, Value and Growth folks see the world differently. For Growth investors, the valuation (e.g. P/E ratio) one pays today tends to take a back seat to whether metrics like revenue, earnings, customers, et cetera are expected to grow at a satisfactory rate. Other market participants tend to have similarly high expectations for these companies, forcing investors to pay “expensive” relative prices for their shares. To see prices rise, Growth stocks must grow their businesses and meet often-lofty targets, leaving little margin for error.

Value investors prefer to pay less than market rates for their shares, enabling shareholders to make money two ways. The first occurs when a stock’s multiples revert to the historical average of the company/industry/market, often spurred by improving investor sentiment. For example, a stock might trade at a ‘discounted’ 10x P/E ratio, while the norm is 15x. Should the stock earn the normal multiple and earnings stay constant, the stock price will rise, even though there was no change to the underlying business. The second is growth in the bottom line, which can be aided by an upswing in cyclical trends, a weathering or reduction in headwinds, business restructuring and/or better management execution.

In the latest Special Report on the subject, I offer additional rationale in support of Value.

And below I detail two stocks we just bought for TPS Portfolio, the flagship, real-money portfolio that has been at the heart of The Prudent Speculator since the newsletter’s founding in 1977!

HIGH-YIELDING PHARMA TITAN

Pfizer
PFE
is a global pharmaceutical titan that focuses on a variety of innovative therapies and vaccinations. Pfizer has also been in the race to develop an oral diabetes/weight loss treatment to compete with currently approved injectable drugs with rapidly growing popularity produced by two competitors.

Recently, PFE shareholders were also reminded that Uncle Sam can giveth and taketh away (almost simultaneously), with President Biden saying he would seek new funding from Congress for an updated COVID-19 vaccine as new mutations of the virus reveal themselves, even as the jointly-produced medication Eliquis was selected as one of the first 10 for mandated 2026 Medicare price negotiations.

Push and pull with regulators, governments, competitors and even society will always be present, but I think Pfizer’s foundation is solid, based on strong cash flows derived from a diverse basket of drugs. I also find the current multiple of 12 times NTM EPS and large dividend yield of 4.8% attractive for the scale, portfolio of existing products and drug pipeline with more than 20 therapies in Phase 3 trials.

FORMER GROWTH STOCK NOW A VALUE NAME

PayPal
PYPL
provides digital and mobile payment solutions in three main segments: Wallet & Commerce, Network and Payment Service Provider (PSP). PayPal serves 400 million individuals and 35 million merchants in 200+ countries, offering the option of 150 currencies for sending and 25 for holding funds. In Q2, PYPL handled 6.1 billion transactions and $377 billion of payment volume, with the company’s Venmo brand growing rapidly thanks to new features like Tap to Pay for Venmo (which allows digital wallets including Apple Pay), Venmo Teen Accounts for parental oversight and Venmo at checkout.

Since July 2021, investors have headed for the exits and shares have fallen 80%, creating today’s discounted purchase opportunity. This is especially true as PayPal gets its new leader this month in Alex Chriss from Intuit
INTU
, where he successfully grew the company’s $8 billion small business segment. I believe PYPL offers differentiated financial exposure to a broadly diversified portfolio and I like the inexpensive price (11.9 times NTM earnings), healthy balance sheet and active share repurchase program (~$5 billion for 2023).

Read the full article here

News Room September 8, 2023 September 8, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
EU will lose ‘race to the bottom’ on regulation, says competition chief

Stay informed with free updatesSimply sign up to the EU business regulation…

“It’s a very bad bet to bet against US companies”: Analyst

Watch full video on YouTube

We Went To Intel’s Arizona Chip Fab To See If It Can Regain Its Edge

Watch full video on YouTube

Columbia Short Term Bond Fund Q3 2025 Commentary (Mutual Fund:NSTRX)

Columbia Threadneedle Investments is a leading global asset management group that provides…

GM’s tariff turnaround is “staggering”: Analyst

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Nursing Home Stocks Could Suffer from this Medicaid Spending Remedy

By News Room
Investing

Bitcoin Drops Below $90,000 Again. What Could Move It Next.

By News Room
Investing

These Stocks Are Moving the Most Today: Marvell, Nvidia, Broadcom, GM, Tesla, MongoDB, Burlington, and More

By News Room
Investing

Nvidia Stock Falls as Marvell Earnings Compound AI Gloom. The Rising Risks for Chips.

By News Room
Investing

This analyst says Tesla deliveries will be 16% below expectations. Musk is part of the problem.

By News Room
Investing

BP CEO was awarded no bonus pay from oil giant’s financial performance

By News Room
Investing

Shares of Starlink’s European competitor have tripled. CEO says it can do the job in Ukraine.

By News Room
Investing

GE Vernova Stock Rises as Analyst Flips to Upgrade After Rating Cut

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?